Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Zydus lifesciences - You Need To See This

Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked target

Shares of Zydus Lifesciences saw a decline of more than two percent following the announcement of a notable profit drop. The net profit plunged thirty-six percent year-on-year for the first quarter, despite a nearly twenty-two percent increase in operational revenue. Expenses surged by over forty-one percent. However, the managing director…

The Economic Times

Zydus Lifesciences Q1 Results: Net profit down 36% at Rs 939.8 crore

Zydus Lifesciences reported a significant year-on-year decline of thirty-six percent in net profit for the first quarter, despite a robust twenty-two percent increase in operational revenue, reaching eight thousand seventeen crore rupees. The company experienced profitability challenges with an EBITDA reduction of seven point six percent compared to the previous…

The Economic Times

Dividend alert! Last day to buy Bharti Airtel, Hero MotoCorp, among 43 stocks for dividend payout worth Rs 1,127

As per Sebi's T+1 settlement cycle, investors must buy a company's shares at least one trading day before the record date to ensure the shares are credited to their demat accounts in time, and they become eligible for the corporate action

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Capitalmind Flexi Cap Fund drops Vedanta Power, Vedanta Iron & Steel and 8 other stocks in June. Check details

Capitalmind Flexi Cap Fund completely exited 10 stocks, including Vedanta Power and Vedanta Iron and Steel, in June while adding seven new names such as JSW Steel, Apollo Hospitals Enterprise, and Zydus Lifesciences. The fund increased exposure to five stocks and made no reductions elsewhere. It held 35 stocks across…

The Economic Times

Zydus Lifesciences ties up with Apollo Hospitals to offer Shield multi-cancer detection test

Zydus Lifesciences has partnered with Apollo Hospitals to introduce the Shield multi-cancer detection test in India, made possible through an agreement with Guardant Health. This innovative blood test can identify signals for multiple cancer types in individuals aged 45 and above. The collaboration aims to enhance early cancer detection and…

The Economic Times

Zydus, Sunshine to set up $20 million pharma JV in Sri Lanka

Indian pharmaceutical giant Zydus Lifesciences has partnered with Sri Lanka's Sunshine Healthcare Lanka to establish a new manufacturing facility. This $20 million joint venture, Zydus Sunshine Lifesciences, will be located in the Horana Export Processing Zone. The project aims to boost local drug production, decrease reliance on imports, and improve…

The Economic Times

Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 million

Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a wholly-owned entity, bolstering Zydus's specialty and oncology supportive-care therapies pipeline. This strategic move aims to enhance the company's innovative drug offerings.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Zydus Lifesciences, 2 other share buybacks closing today. Are you participating?

Investors have a final opportunity to tender shares in buyback offers from Zydus Lifesciences, Dhanuka Agritech, and CyberTech Systems and Software. These offers, collectively valued at approximately Rs 1,185 crore, are closing on Wednesday. Eligible shareholders can participate in these corporate actions, which represent a chance to sell shares at…

The Economic Times

Zydus Lifesciences hikes share buyback price to Rs 1,260 per share, lowers share count

Zydus Lifesciences increased its share buyback price to Rs 1,260 per share while reducing the repurchase size to 87.3 lakh shares. The total buyback outlay remains Rs 1,100 crore. The pharma stock has outperformed benchmark indices over the past one year with a 19% rally.

The Economic Times

Zydus Lifesciences buyback alert! Last date to buy shares to participate in Rs 1,100 crore buyback at 7% premium

Investors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date is May 29. The company approved buying back up to 95.65 lakh shares at Rs 1,150 each, a 7% premium. This follows strong Q4 results and a…

The Economic Times

Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the…

The Economic Times

Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?

Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pharma index rebounded from early losses to rise nearly 1%, crossing the 25,000 mark and hitting a fresh 52-week high of 25,043.

The Economic Times

Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?

Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's…

The Economic Times

Zydus Lifesciences' Rs 1,100 crore share buyback at 13% premium: Check record date, other details

Zydus Lifesciences is launching its largest share buyback program to date. The company plans to repurchase shares worth Rs 1,100 crore. This move offers shareholders a premium price. The record date for eligibility is May 29. The buyback will be conducted through a tender route. This follows previous successful buyback…

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Market Trading Guide: Buy Zydus Lifesciences, Solar Industries on Friday for gains up to 15%

Nifty 50 closed higher for a second straight session, driven by banking, metal and pharma stocks despite IT weakness. Analysts see 23,800 as a crucial resistance level, while recommending Zydus Lifesciences and Solar Industries India for near-term gains on strong technical indicators and bullish momentum.

The Economic Times

Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisition

Zydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. The stock also gained momentum as Zydus announced a $166 million acquisition of US-based Assertio. Investor sentiment improved on expectations of capital return and strategic business…

The Economic Times

Stocks in news: HAL, TMPV, Bharti Airtel, Anant Raj, Zydus Life, Tata Motors

Indian markets experienced a volatile yet stable session after a sharp sell-off, with the Nifty showing resilience. Key companies like HAL, Tata Motors, and Bharti Airtel are in focus due to quarterly results and news developments. Zydus Lifesciences is nearing a US acquisition, while Maruti Suzuki commits to green logistics.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.